Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-07-11
DOI
10.1038/s41598-017-06002-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity
- (2017) Gerhard Hamilton et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Pembrolizumab in Non–Small-Cell Lung Cancer
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
- (2017) Shuguang Tan et al. Nature Communications
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
- (2016) Wojciech G. Lesniak et al. BIOCONJUGATE CHEMISTRY
- Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
- (2016) Kefang Liu et al. CELL RESEARCH
- Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
- (2016) Zhenkun Na et al. CELL RESEARCH
- A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study
- (2016) David Planchard et al. Clinical Lung Cancer
- From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway
- (2016) Mei-Miao Zhan et al. DRUG DISCOVERY TODAY
- Targeting T Cell Co-receptors for Cancer Therapy
- (2016) Margaret K. Callahan et al. IMMUNITY
- Anti-PD-L1 inhibitor durvalumab in bladder cancer
- (2016) Vicki Brower LANCET ONCOLOGY
- Atezolizumab: an alternative to cisplatin?
- (2016) Peter Sidaway Nature Reviews Clinical Oncology
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
- (2016) Ju Yeon Lee et al. Nature Communications
- High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1
- (2016) Shoichiro Horita et al. Scientific Reports
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Nivolumab for the treatment of cancer
- (2014) Anasuya Gunturi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
- (2014) Yanping Xiao et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor
- (2013) Xiaoxiao Cheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer
- (2013) Julie R. Brahmer JOURNAL OF CLINICAL ONCOLOGY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
- (2010) Carol M Lee et al. BMC CANCER
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions
- (2009) O Akbari et al. Mucosal Immunology
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
- (2008) D. Y.-w. Lin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now